These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 7855620

  • 1. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
    Parkinson DR, Sznol M.
    Semin Oncol; 1995 Feb; 22(1):61-6. PubMed ID: 7855620
    [No Abstract] [Full Text] [Related]

  • 2. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA, Benyunes MC, Bianco JA, Fefer A.
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract] [Full Text] [Related]

  • 3. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
    Pierce WC, Belldegrun A, Figlin RA.
    Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
    [No Abstract] [Full Text] [Related]

  • 4. Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.
    Stadler WM, Vogelzang NJ.
    Semin Oncol; 1995 Feb; 22(1):67-73. PubMed ID: 7855621
    [No Abstract] [Full Text] [Related]

  • 5. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
    Figlin RA, Pierce WC, Belldegrun A.
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
    Stoter G, Goey SH, Batchelor D, Eggermont AM, Lamers C, Gratama JW, Bolhuis RL.
    Prog Clin Biol Res; 1992 Dec; 378():225-33. PubMed ID: 1301583
    [No Abstract] [Full Text] [Related]

  • 7. Rapid exacerbation of scleroderma in a patient treated with interleukin 2 and lymphokine activated killer cells for renal cell carcinoma.
    Puett DW, Fuchs HA.
    J Rheumatol; 1994 Apr; 21(4):752-3. PubMed ID: 8035405
    [Abstract] [Full Text] [Related]

  • 8. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF, Aramendía JM, Alonso G, Foncillas JG, Brugarolas A.
    Rev Med Univ Navarra; 1996 Apr; 40(3):6-12. PubMed ID: 9499820
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
    Parkinson DR, Fisher RI, Rayner AA, Paietta E, Margolin KA, Weiss GR, Mier JW, Sznol M, Gaynor ER, Bar MH.
    J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
    [Abstract] [Full Text] [Related]

  • 11. Interleukin-2.
    Med Lett Drugs Ther; 1990 Sep 07; 32(826):85-6. PubMed ID: 2202892
    [No Abstract] [Full Text] [Related]

  • 12. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
    Linehan WM, Walther MM, Alexander RB, Rosenberg SA.
    Semin Urol; 1993 Feb 07; 11(1):41-3. PubMed ID: 8465127
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of metastatic renal cell carcinoma with recombinant interleukin-2 in combination with vinblastine or lymphokine-activated killer cells.
    Kuebler JP, Whitehead RP, Ward DL, Hemstreet GP, Bradley EC.
    J Urol; 1993 Sep 07; 150(3):814-20. PubMed ID: 8345590
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. IL-2 therapy proves durable in renal cell melanoma patients.
    Oncology (Williston Park); 1991 Sep 07; 5(9):71. PubMed ID: 1835879
    [No Abstract] [Full Text] [Related]

  • 16. Anti-tumor effects of interleukin 2 against renal cell carcinoma. In vitro study and clinical application.
    Marumo K, Tazaki H.
    Prog Clin Biol Res; 1990 Sep 07; 350():263-73. PubMed ID: 2117286
    [No Abstract] [Full Text] [Related]

  • 17. [Cell therapy in renal cell carcinoma].
    Ravaud A.
    Bull Cancer; 2003 Sep 07; 90(8-9):711-21. PubMed ID: 14609761
    [Abstract] [Full Text] [Related]

  • 18. Renal cell carcinoma: current status and future plans.
    Figlin RA.
    Cancer J Sci Am; 2000 Feb 07; 6 Suppl 1():S52-4. PubMed ID: 10685659
    [No Abstract] [Full Text] [Related]

  • 19. Interleukin 2 and psoriasis.
    Lee RE, Gaspari AA, Lotze MT, Chang AE, Rosenberg SA.
    Arch Dermatol; 1988 Dec 07; 124(12):1811-5. PubMed ID: 3263840
    [Abstract] [Full Text] [Related]

  • 20. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC, Rosenberg SA.
    Cancer J Sci Am; 1997 Dec 07; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.